FDA approves generic blood thinner

Jul 26, 2010 By Andrew Zajac

In a closely watched decision, the Food and Drug Administration on Friday approved an application by German drug-maker Sandoz and Momenta Pharmaceuticals of Cambridge, Mass, to make the first generic version of the widely used blood thinner Lovenox.

The approval positions Momenta and Sandoz to offer a cheaper but still lucrative alternative to Lovenox, which had sales of $4.5 billion in 2009, making it the 15th best selling drug in the world.

In its decision, the FDA also rejected an argument by Lovenox's maker, Sanofi-Avenis, that its drug, which is made from found in heparin, a substance derived from pig intestines, is too complex to be copied with precision by makers of generic versions of the medication.

The Sandoz/Momenta team had been in a bitter, five-year battle with Amphastar Pharmaceuticals, of Rancho Cucamonga, Calif., to win the FDA's nod to make the drug, which goes by the generic name enoxaparin.

Amphastar last year accused Janet Woodcock, the FDA's top drug official, of a conflict of interest involving her past associations with Momenta scientists. The complaint was dismissed by the Department of Health and Human Services Inspector General.

"The approval of M-enoxaparin marks a key milestone for Momenta and we are extremely pleased," Momenta CEO Craig Wheeler said in a statement.

Shares of Momenta, which supplied the technology in its partnership, zoomed to $21.70, up $9.77, an increase of more than 80 percent. Shares of Sandoz' parent, Swiss pharma conglomerate Novartis, closed down 35 cents at $49.21.

Sanofi shares lost $1.29, closing at $29.35.

The contours of the FDA announcement could bode well for Momenta, according to analyst Bret Holley, of Oppenheimer Co.

The Momenta's partnership agreement with Sandoz is much more generous if their application is the only one approved, Holley said.

Typically, Holley said, when the FDA rejects a petition by a drug's original maker as it did with Sanofi Avenis, it announces all the generic approvals at the same time, suggesting that Sandoz/Momenta might be the only application slated for approval.

Holley also said that the painstaking review of the Sanofi Avenis request, conveyed in a 45-page letter, suggests that the FDA will move cautiously when considering generic versions of drugs derived from natural substances.

"I don't believe that they're going to be approving applications (for biogenerics) willy-nilly," he said.

Amphastar attorney Jason Shandell declined to specify his company's next move, but hinted that it was not ready to throw in the towel.

"As the first filer, we're obviously very disappointed and we will do everything we can to allow the system to correct such a mistake," Shandell said. Amphastar applied to make enoxaparin in 2003, two years earlier than Sandoz/Momenta.

The FDA still could approve Amphastar's application, but the company would not have first-mover advantage and would be competing against the global distribution capabilities of Sandoz.

Amphastar's allegation of a involving Woodcock centered on her partnering with Momenta scientists in investigating the crisis in early 2008 in which contaminated lots of the drug from China sickened, and in some cases killed, patients.

Amphastar argued that the collaboration and earlier contacts between Woodcock and Momenta scientists inclined the FDA to favor Momenta.

Momenta has said that there is nothing inappropriate in its relationship with regulators.

Explore further: New treatment approved for rare form of hemophilia

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

FDA approves generic AIDS drug

Dec 20, 2007

The U.S. Food and Drug Administration has given tentative approval for a generic version of the AIDS drug Viread.

Generic pediatric AIDS Drug gets U.S. OK

Jun 28, 2006

The U.S. Food and Drug Administration has tentatively approved the generic version of Abacavir Sulfate Oral Solution for use by pediatric AIDS victims.

Wyeth sues FDA to block rival generic antibiotic

Sep 23, 2009

(AP) -- Drugmaker Wyeth on Wednesday sued the Food and Drug Administration to block the sale of a generic rival to its intravenous antibiotic Zosyn, claiming the generic is not an equivalent product and could harm critically ...

FDA tells doctors new heparin formula less potent

Oct 01, 2009

(AP) -- The Food and Drug Administration is alerting doctors that a widely used blood thinner has been reformulated to improve its safety, though the change could open the door to dosing errors.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments : 0